CCP
NEXI

Corient Capital Partners’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Corient Capital Partners’s Portfolio NEXI Stock Details NEXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-675
Closed -$71K – 777
2022
Q1 		$71K Buy
+675
New +$49.6K ﹤0.01% 728

Other funds holding NEXI

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AO
Allen Operations New York $670M AUM 26.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
KHCM
Kettle Hill Capital Management New York $399M AUM 10.05% 1-Year Est. Return

Corient Capital Partners's NEXI Position: Q2 2022 in Review

Corient Capital Partners sold out of NexImmune, Inc. Common Stock (NEXI) in Q2 2022, closing a stake of 675 shares — an estimated $71K sold.

Corient Capital Partners first reported a position in NEXI in Q1 2022 and held it in 1 quarter. The position peaked at $71K in Q1 2022. 44 funds tracked by Wall St. Rank hold NEXI as of Q2 2022.

  • Corient Capital Partners reported no remaining NexImmune, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Corient Capital Partners sold 675 NexImmune, Inc. Common Stock shares in Q2 2022, an estimated $71K.
  • Corient Capital Partners first reported a position in NexImmune, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Corient Capital Partners's NexImmune, Inc. Common Stock position peaked at $71K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.